The aim of the call is to support the clinical validation and evaluation of breakthrough technologies that can increase the proportion of cancers which are detected earlier in the disease course and/or target health inequalities in stage of cancer diagnosis.
Funding will be deployed to facilitate the generation of evidence on safety, test performance characteristics, clinical efficacy and/or effectiveness that can support regulatory approvals requirements and subsequent clinical implementation or implementation research. Applications that address health inequalities in early cancer diagnosis are particularly welcomed.
The Cancer Mission: Early Cancer Diagnosis Clinical Validation and Evaluation Call is a one-stage call inviting applications for projects up to 36 months in duration, with no upper funding limit.
The call will be open to organisations which are UK legal entities, that have an innovative solution with the potential to increase the proportion of cancers diagnosed at stages 1 and 2. This call is open to small/medium commercial entities, NHS and Third Sector Service Providers, charitable organisations, local government bodies, as well as universities and research institutions.
More information can be found in the call specification.
The application window will open on October 24th 2023, 13:00 and will close on December 12th 2023, 13:00.
Register for the launch event – 6 October
A launch event will be held on Friday 6 October, please register via eventbrite to attend.